ULTRAGENYX PHARMACEUTICAL INC. Deferred Tax Assets, Operating Loss Carryforwards
ULTRAGENYX PHARMACEUTICAL INC. (RARE) had Deferred Tax Assets, Operating Loss Carryforwards of $511.00 million as of 2025-12-31, per its 10-K filed 2026-02-18.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Operating Loss Carryforwards, Components
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-02-18
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $511.00M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $309.00M; Deferred Tax Assets, Operating Loss Carryforwards as first filed $309.30M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $266.25M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $231.84M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards | Deferred Tax Assets, Operating Loss Carryforwards as first filed |
|---|---|---|
| 2025-12-31 | $511.00M 10-K · filed 2026-02-18 | |
| 2024-12-31 | $309.00M 10-K · filed 2026-02-18 | $309.30M 10-K · filed 2025-02-19 |
| 2023-12-31 | $266.25M 10-K · filed 2025-02-19 | |
| 2022-12-31 | $231.84M 10-K · filed 2024-02-21 | |
| 2021-12-31 | $306.12M 10-K · filed 2023-02-17 | |
| 2020-12-31 | $222.90M 10-K · filed 2022-02-15 | |
| 2019-12-31 | $185.89M 10-K · filed 2021-02-12 | |
| 2018-12-31 | $183.33M 10-K · filed 2020-02-14 | |
| 2017-12-31 | $154.95M 10-K · filed 2019-02-20 | |
| 2016-12-31 | $102.96M 10-K · filed 2018-02-21 | |
| 2015-12-31 | $61.50M 10-K · filed 2017-02-17 | |
| 2014-12-31 | $32.50M 10-K · filed 2016-02-26 | |
| 2013-12-31 | $16.35M 10-K · filed 2015-03-27 | |
| 2012-12-31 | $200.00K 10-K · filed 2023-02-17 | $300.00K 10-K · filed 2016-02-26 |
| 2011-12-31 | $200.00K 10-K · filed 2023-02-17 | $300.00K 10-K · filed 2016-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |